Search
Research
Dendritic cells and cancer: From biology to therapeutic interventionIn this review, we discuss the different subsets of tumor-infiltrating dendritic cells and their role in anti-tumor immunity
Research
CD8+XCR1neg Dendritic Cells Express High Levels of Toll-Like Receptor 5 and a Unique Complement of Endocytic ReceptorsOur data demonstrate that CD8+XCR1neg DCs possess a unique pattern of endocytic receptors and a restricted TLR profile that is particularly enriched for TLR5
Research
IFNβ inhibits the development of allergen tolerance and is conducive to the development of asthma on subsequent allergen exposureData indicate a role for Interferonβ in linking viral infection and allergy
Research
Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitorsEarly changes in cell morphology upon treatments are a strong indication that the inhibitor is directly targeting tubulin
Research
Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103− and XCR1+CD103+ dendritic cellsThis report provides new insight into the functional specialization within the broad network of dendritic cells that are responsible for skin immunosurveillance
Research
The Immune Response to Skin Trauma Is Dependent on the Etiology of Injury in a Mouse Model of Burn and Excision.This article investigates the impact of burn & excisional injury on the immune system.
Research
T cells recognizing a 11mer influenza peptide complexed to H-2D b show promiscuity for peptide lengthT-cell repertoire is selected according to self peptide-MHC (major histocompatibility complex) complexes in the thymus.
Research
Prostaglandin E2 imprints a long-lasting effect on dendritic cell progenitors in the bone marrowInjection of BM-differentiated DCs from nonchimeric mice restored the reduced immune responses of PGE2-chimeric mice.
Research
Making a Killer: Selecting the Optimal Natural Killer Cells for Improved ImmunotherapiesOver the past 20 years natural killer (NK) cell-based immunotherapies have emerged as a safe and effective treatment option for patients with relapsed or refractory leukemia. Unlike T cell-based therapies, NK cells harbor an innate capacity to eliminate malignant cells without prior sensitization and can be adoptively transferred between individuals without the need for extensive HLA matching.
Research
Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in gliomaWe discovered a previously unknown major resistance mechanism in glioma in that most EGFR domain III-targeting antibodies do not neutralize EGFRvIII